These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 31005939)

  • 21. The relationship between clinical characteristics including presence of exposed lesions and health-related quality of life (HRQoL) in patients with psoriasis: analysis from the nationwide epidemiologic study for psoriasis in Korea (EPI-PSODE study).
    Youn SW; Lee JH; Yu DY; Kim Y; Kim BS; Seo SJ; Choe YB; Yun SK; Park J; Kim NI; Choi CW; Youn JI; Lee SJ; Lee MG; Kim KJ; Park CJ; Ro YS; Song HJ; Shin BS; Ahn SK; Lee JY; Won YH; Jang MS; Kim KH; Kim MH; Kim TY; Choi JH
    J Eur Acad Dermatol Venereol; 2018 Sep; 32(9):1499-1506. PubMed ID: 29430733
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Work productivity in real-life employed patients with plaque psoriasis: Results from the ProLOGUE study.
    Saeki H; Kanai Y; Murotani K; Ito K; Miyagi T; Takahashi H; Tada Y; Higashiyama M; Hashimoto Y; Kitabayashi H; Imafuku S
    J Dermatol; 2022 Oct; 49(10):970-978. PubMed ID: 35856276
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis.
    Revicki DA; Willian MK; Menter A; Gordon KB; Kimball AB; Leonardi CL; Langley RG; Kimel M; Okun M
    J Dermatolog Treat; 2007; 18(6):341-50. PubMed ID: 18058494
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association Between Quality of Life and Improvement in Psoriasis Severity and Extent in Pediatric Patients.
    Bruins FM; Bronckers IMGJ; Groenewoud HMM; van de Kerkhof PCM; de Jong EMGJ; Seyger MMB
    JAMA Dermatol; 2020 Jan; 156(1):72-78. PubMed ID: 31774449
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Health-related quality of life in patients with generalized pustular psoriasis - a Swedish register study.
    Norlin JM; Löfvendahl S; Schmitt-Egenolf M
    Ann Med; 2024 Dec; 56(1):2341252. PubMed ID: 38738413
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The National Psoriasis Foundation psoriasis treatment targets in real-world patients: prevalence and association with patient-reported outcomes in the Corrona Psoriasis Registry.
    Merola JF; Perez Chada LM; Siegel M; Bagel J; Evans C; Lockshin B; Mason M; Guo N; McLean RR; Greenberg JD; Van Voorhees AS
    J Eur Acad Dermatol Venereol; 2020 Sep; 34(9):2051-2058. PubMed ID: 32027420
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Minimal clinically important difference (MCID) for work productivity and activity impairment (WPAI) questionnaire in psoriasis patients.
    Wu JJ; Lin C; Sun L; Goldblum O; Zbrozek A; Burge R; Augustin M; Feldman SR
    J Eur Acad Dermatol Venereol; 2019 Feb; 33(2):318-324. PubMed ID: 29846976
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of secukinumab on patient-reported outcomes in biologic-naive patients with psoriasis in a US real-world setting.
    Strober B; Patil D; McLean RR; Moore-Clingenpeel M; Guo N; Levi E; Lebwohl M
    J Dermatolog Treat; 2022 Dec; 33(8):3178-3187. PubMed ID: 36026543
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial.
    Kimball AB; Bensimon AG; Guerin A; Yu AP; Wu EQ; Okun MM; Bao Y; Gupta SR; Mulani PM
    Am J Clin Dermatol; 2011 Feb; 12(1):51-62. PubMed ID: 21110526
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of Ixekizumab Treatment on Work Productivity for Patients With Moderate-to-Severe Plaque Psoriasis: Analysis of Results From 3 Randomized Phase 3 Clinical Trials.
    Armstrong AW; Lynde CW; McBride SR; Ståhle M; Edson-Heredia E; Zhu B; Amato D; Nikaï E; Yang FE; Gordon KB
    JAMA Dermatol; 2016 Jun; 152(6):661-9. PubMed ID: 26953848
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential effects of secukinumab vs. ustekinumab for treatment of psoriasis on quality of life, work productivity and activity impairment: a structural equation modelling analysis.
    Stull DE; Griffiths CEM; Gilloteau I; Zhao Y; Guana A; Finlay AY; Sherif B; Houghton K; Puig L
    Br J Dermatol; 2018 Jun; 178(6):1297-1307. PubMed ID: 29355896
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study.
    Shikiar R; Willian MK; Okun MM; Thompson CS; Revicki DA
    Health Qual Life Outcomes; 2006 Sep; 4():71. PubMed ID: 17005043
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improved Quality of Life in Patients with Psoriasis Receiving Apremilast: Real-World Data from the Netherlands.
    van den Reek JMPA; van der Leest RJT; Thomas SE; Prevoo R; Plantenga ME; de Jong EMGJ
    Adv Ther; 2024 Apr; 41(4):1594-1605. PubMed ID: 38402373
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasis.
    Menter A; Kosinski M; Bresnahan BW; Papp KA; Ware JE
    J Drugs Dermatol; 2004; 3(1):27-38. PubMed ID: 14964744
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Disease severity, treatment patterns, and quality of life in patients with moderate-to-severe psoriasis routinely managed with systemic treatment: results of the CRYSTAL observational study in Central and Eastern European countries.
    Raam L; Hartmane I; Valiukevičienė S; Karamova AE; Telegdy E; Botev I; Marina D; Rubant S; Albuquerque T; Constantin MM
    Front Immunol; 2024; 15():1410540. PubMed ID: 38846952
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of Fatigue on Health-Related Quality of Life and Work Productivity in Psoriatic Arthritis: Findings From a Real-World Survey.
    Gossec L; Walsh JA; Michaud K; Holdsworth E; Peterson S; Meakin S; Yang F; Booth N; Chakravarty SD; Piercy J; Dennis N; Ogdie A
    J Rheumatol; 2022 Nov; 49(11):1221-1228. PubMed ID: 35840154
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis.
    Revicki D; Willian MK; Saurat JH; Papp KA; Ortonne JP; Sexton C; Camez A
    Br J Dermatol; 2008 Mar; 158(3):549-57. PubMed ID: 18047521
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patient-reported Outcomes During Treatment in Patients with Moderate-to-severe Psoriasis: A Danish Nationwide Study.
    Loft ND; Egeberg A; Rasmussen MK; Bryld LE; Gniadecki R; Dam TN; Iversen L; Skov L
    Acta Derm Venereol; 2019 Dec; 99(13):1224-1230. PubMed ID: 31580465
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Disease response and patient-reported outcomes among initiators of ixekizumab.
    Shahriari M; Harrison RW; Burge R; Lin CY; Malatestinic WN; Goldblum OM; McLean RR; Crabtree MM; O'Brien J; Grace EL; Murage MJ
    J Dermatolog Treat; 2022 May; 33(3):1538-1546. PubMed ID: 33267635
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of the Dermatology Life Quality Index work/study domain to estimate overall work productivity loss among patients with psoriasis: an analysis based on real-world data.
    Li N; Teeple A; Muser E; Lucas J; Hetherington J; Fitzgerald T
    Clin Exp Dermatol; 2020 Jul; 45(5):572-575. PubMed ID: 31736108
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.